Arcus Biosciences Inc (RCUS)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-307,000	-293,000	-287,000	-279,000	-267,000	79,538	66,563	57,593	53,000	-278,391	-198,594	-167,698	-122,858	-87,603	-111,777	-94,793	-84,710	-80,407	-68,867	-54,310
Revenue (ttm)	US$ in thousands	117,000	119,355	121,236	118,995	112,000	433,144	408,724	399,137	398,304	53,292	108,361	92,939	77,517	77,780	15,000	15,000	15,000	6,812	9,353	8,853
Net profit margin		-262.39%	-245.49%	-236.73%	-234.46%	-238.39%	18.36%	16.29%	14.43%	13.31%	-522.39%	-183.27%	-180.44%	-158.49%	-112.63%	-745.18%	-631.95%	-564.73%	-1,180.37%	-736.31%	-613.46%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $-307,000K ÷ $117,000K
= -262.39%

Arcus Biosciences Inc's net profit margin has been negative for all quarters in 2023, ranging from -234.47% to -262.39%. This indicates that the company's expenses have exceeded its revenues by a significant margin, resulting in substantial net losses. The trend of increasing negative net profit margins throughout 2023 raises concerns about the company's financial performance and its ability to generate profits from its operations. In contrast, in 2022, Arcus Biosciences Inc had positive net profit margins ranging from 14.67% to 18.44%, showcasing a stark decline in profitability within a year. The company may need to reevaluate its cost structure, revenue generation, and overall business strategies to improve its financial health and return to sustainable profitability.